8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 6, 2008

Targeted Genetics Corporation

(Exact name of registrant as specified in its charter)

Washington	0-23930	91-1549568
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

1100 Olive Way, Suite 100, Seattle, Washington	98101
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code (206) 623-7612

Not Applicable

(Former name or former address if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On November 6, 2008, the Board of Directors accepted the resignation of H. Stewart Parker as the chief executive officer and president of Targeted Genetics effective November 6, 2008. Ms. Parker remains on the company’s board of directors. The Board of Directors also accepted the resignation of Barrie J. Carter as the executive vice president and chief scientific officer of Targeted Genetics effective November 6, 2008. Ms. Parker managed Targeted Genetics formation as a wholly owned subsidiary of Immunex Corporation in 1989 and served as Targeted Genetics’ president, chief executive officer and a director since that time. Dr. Carter served as Targeted Genetics’ executive vice president since August 1992 and as Targeted Genetics’ chief scientific officer since January 2001.

On November 6, 2008, the Board of Directors appointed B. G. Susan Robinson as Targeted Genetics’ president and chief executive officer.

B. G. Susan Robinson, age 47, has served as Targeted Genetics’ vice president of business development since December 2001. Ms. Robinson joined Targeted Genetics in March, 2000 as the company’s senior director of business development. Prior to joining Targeted Genetics, she was director, business development at Genzyme Molecular Oncology, a business unit of Genzyme Corporation from 1997 to 2000. In her business development roles, she has completed multiple corporate and academic technology licenses, sponsored research agreements, and product development collaboration agreements. From 1988 to 1997, Ms. Robinson held increasingly responsible positions in corporate development and corporate communications for Immulogic Pharmaceuticals Corporation and T-Cell Sciences, Inc. (now Celldex). Ms. Robinson is a graduate of Yale University.

Item 9.01.      Financial Statements and Exhibits.

Exhibits.

99.1 Press Release of Targeted Genetics Corporation dated November 10, 2008

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	TARGETED GENETICS CORPORATION
Dated: November 10, 2008	By:	/s/ DAVID J. POSTON
		David J. Poston Vice President Finance and Chief Financial Officer

INDEX TO EXHIBITS

Exhibit Number	Description
99.1	Press Release of Targeted Genetics Corporation dated November 10, 2008

EX-99.1

®

Targeted Genetics Board of Directors Names B.G. Susan Robinson as President and CEO

- H. Stewart Parker, President and Chief Executive Officer and Barrie J. Carter, PhD, Executive Vice President and Chief Scientific Officer Step Down -

SEATTLE, Wash., November 10, 2008— Targeted Genetics Corporation (NASDAQ: TGEN) announced today that H. Stewart Parker, President, Chief Executive Officer and Barrie J. Carter, PhD, Executive Vice President and Chief Scientific Officer have resigned effective November 6, 2008. Ms. Parker remains on the Board of Directors. The Board of Directors has appointed B.G. Susan Robinson, as the Company’s President and Chief Executive Officer. Ms. Robinson joined Targeted Genetics in March 2000 and previously served as Vice President of Business Development.

“On behalf of the Board, I would like to express our genuine thanks to and esteem for Ms. Parker and Dr. Carter for their dedication and perseverance through some very gratifying and challenging times,” said Jeremy Curnock Cook, Chairman of the Board. “Over the past seventeen years Ms. Parker and Dr. Carter have pioneered the development of gene transfer from the lab bench towards commercialization, and were responsible for the first clinical trials conducted using AAV. They have also played critical roles in the general development of the field through their work with FDA committees and the Biotechnology Industry Organization.”

“Although I look forward to taking on new challenges, I am honored to have worked with some of the best and brightest people in the industry and am proud of the scientific and clinical achievements we have made here to advance and validate the potential of gene therapy,” said Ms. Parker. “I wish the entire Targeted Genetics team great success in continuing the important work we have achieved to date.”

For most of this decade, Ms. Robinson has led licensing and partnering activities for Targeted Genetics. In this role, she has been integrally involved in strategic transaction activities, corporate development and all aspects of the strategic planning function for the Company. “I welcome the opportunity to work with our board, employees and collaborators to capitalize on the opportunity we have to create real value from our leading-edge AAV technology. We will be intently focused on efforts to extend our cash horizon in order to advance development of our innovative, robust pipeline and ultimately bring to market our exciting product opportunities,” said Ms. Robinson.

“We have full confidence in Ms. Robinson and the rest of the team as we work to advance our valuable platform and product pipeline,” said Jeremy Curnock Cook.

Prior to joining Targeted Genetics, Ms. Robinson was Director, Business Development at Genzyme Molecular Oncology, part of Genzyme Corporation. In her business development roles, she has completed multiple corporate and academic technology licenses, sponsored research agreements, and product development collaboration agreements. Prior to Genzyme, and over a nine-year period, Ms. Robinson held increasingly responsible positions in corporate development and corporate communications for Immulogic Pharmaceuticals Corporation and T-Cell Sciences, Inc. (now Celldex). Ms. Robinson is a graduate of Yale University.

Ms. Parker managed Targeted Genetics’ formation as a wholly owned subsidiary of Immunex Corporation in 1989 and has served as Targeted Genetics’ president, chief executive officer and a director since that time. Dr. Carter served as Targeted Genetics’ executive vice president since August 1992 and as Targeted Genetics’ chief scientific officer since January 2001.

About Targeted Genetics Corporation

Targeted Genetics Corporation is a biotechnology company committed to the development of innovative, targeted molecular therapies for the prevention and treatment of acquired and inherited diseases with significant unmet medical need. Targeted Genetics’ proprietary Adeno-Associated Virus (AAV) technology platform allows it to deliver genes that encode proteins to increase gene function or RNAi to decrease or silence gene function. Targeted Genetics’ product development efforts target inflammatory arthritis, AIDS prophylaxis, congestive heart failure, Huntington's disease and Leber’s congenital amaurosis. To learn more about Targeted Genetics, visit Targeted Genetics’ website at www.targetedgenetics.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This release contains forward-looking statements regarding the Company's liquidity and financial resources, its ability to fund ongoing and future operations and its business strategy and product development, including statements regarding the Company's ability to extend its cash horizon, advance the its platform and product pipeline and create value from its product candidates and other statements about the Company's plans, objectives, intentions and expectations. These statements involve current expectations, forecasts of future events and other statements that are not historical facts. Inaccurate assumptions and known and unknown risks and uncertainties can affect the accuracy of forward-looking statements. Factors that could affect actual future events or results include, but are not limited to, the risk that the Company will run out of cash earlier than expected, the risk that the Company will not be able to raise capital or secure other financial resources in the near term, the risk that the Company's research and development programs are not successful or are delayed or terminated, the risk that payments anticipated by the Company under product development collaborations and contracts are not earned or received when expected or at all, and the risk that the Company will not be able to maintain its listing on the NASDAQ Capital Market , as well as other risk factors described in its filings with the Securities and Exchange Commission (SEC), including in "Item 1A. Risk Factors" in the Company’s most recent quarterly report on Form 10-Q for the quarter ended September 30, 2008 filed with the SEC. You should not rely unduly on these forward-looking statements, which apply only as of the date of this release. The Company undertakes no duty to publicly announce or report revisions to these statements as new information becomes available that may change the Company's expectations.

# # #

Media Contact:

Stacie D. Byars

WeissComm Partners

206.660.2588

sdbyars@wcpglobal.com